| 摘要 |
<p>Novel farnesyl transferase inhibitors of general formula (I), their preparation and pharmaceutical compositions containing same. In general formula (I), R1 is Y-S-A1 -(Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl or alkoxycarbonyl radical or an R4-S radical in which R4 is an alkyl radical containing 1-4 carbon atoms optionally substituted by a phenyl radical or a radical of general formula (II), in which A1, X1, Y1, R'1, R2, R'2 and R are defined as follows: A1 is an alkylene radical containing 1-4 carbon atoms optionally a substituted at α in the grouping >C(X1)(Y1) with an amino or alkylamino, dialkylamino, alkanylamino or alkoxycarbonylamino radical), X1 and Y1 are each a hydrogen atom or form together with the carbon atom to which they are connected a >C=O grouping, R'1 is hydrogène or methyl, R2 is an alkyl, alkenyl or alkynyl radical containing 1-6 carbon atoms optionally substituted by hydroxy, alkoxy, mercapto, alkylthio, alkylsulfinyl or alkylsulfonyl, with the proviso that when R2 is an alkyl radical substituted by a hydroxy radical, R2 can form a lactone with the carboxy radical at α. R'2 is hydrogen or methyl and R is a hydrogen atom or an optionally substituted alkyl radical or an optionally substituted phenyl radical, whith the proviso that the radical (a) is in position 5 or 6 of the naphthyl ring. These novel products have anti-cancer properties.</p> |
